Insulet Corporation
NASDAQ:PODDMedical - Devices
-$4.17 today
- Market cap
- $9.71B
- Beta
- 1.13
- P/E (TTM)
- 33.2
- EPS (TTM)
- $4.33
Volume 2.09M
Average 1.32M
PODD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Insulet CorporationNASDAQ: PODD
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $88.1M rose 20.0% year over year, behind the +39.2% change in trailing-twelve-month research & development. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at +18.7% a year.
Context
- Research & development amounted to 11.1% of revenue in FY2025, up 0.5 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.0% toward the trailing-twelve-month pace of +39.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 301.1M USD
- Year-over-year change
- +37.1%
- 4-year CAGR
- +17.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 301.1M | +37.1% |
| FY2024 | 2024-12-31 | 219.6M | +7.1% |
| FY2023 | 2023-12-31 | 205M | +13.8% |
| FY2022 | 2022-12-31 | 180.2M | +12.6% |
| FY2021 | 2021-12-31 | 160.1M | — |
Research & Development vs competitors
How PODD compares with its peers on the latest reported figures
- PODD's LTM Jun 2026 research & development of $345.9M is the 2nd highest of the 5 companies compared; the peer median is $112.83M.
- Its year-over-year change of +39.2% is the highest of 5, against a peer median of -3.6%.
- Research & development amounts to 11.3% of revenue for PODD, versus a peer median of 26.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $604M | +6.3% | +7.4% | 12.2% | |
| LTM Jun 2026 | $345.9M | +39.2% | +18.7% | 11.3% | |
| LTM Mar 2026 | $188.1M | -32.4% | +0.9% | 18.3% | |
| LTM Mar 2026 | $37.56M | +32.7% | +3.4% | 34.1% | |
| LTM Mar 2026 | $32.9M | -13.4% | -7.3% | 80.8% | |
| Peer median (excluding PODD) | $112.83M | -3.6% | +2.2% | 26.2% | |
Competitors are the stored peer set for PODD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.31B | 1.7B | 2.07B | 2.71B |
| Cost of Revenue | 346.7M | 499.7M | 537.2M | 625.9M | 768.2M |
| Gross Profit | 752.1M | 805.6M | 1.16B | 1.45B | 1.94B |
| Gross Margin | 68.4% | 61.7% | 68.3% | 69.8% | 71.6% |
| Research & Development | 160.1M | 180.2M | 205M | 219.6M | 301.1M |
| Selling, General & Admin | 466M | 587.8M | 734.9M | 917.2M | 1.17B |
| Operating Expenses | 626.1M | 768M | 939.9M | 1.14B | 1.47B |
| Depreciation & Amortization | 57.4M | 63.2M | 72.8M | 80.8M | 90.4M |
| EBITDA | 139.6M | 109M | 323.6M | 423.7M | 509.6M |
| EBITDA Margin | 12.7% | 8.4% | 19.1% | 20.5% | 18.8% |
| Operating Income | 126M | 37.6M | 220M | 308.9M | 473.8M |
| Operating Margin | 11.5% | 2.9% | 13.0% | 14.9% | 17.5% |
| Interest Income | 500K | 9.3M | 28.6M | 39.5M | 34.7M |
| Interest Expense | 61.7M | 36M | 36.2M | 42.7M | 79.7M |
| Other Income / Expenses | (105.5M) | (27.8M) | (5.4M) | (8.7M) | (134.3M) |
| Income Before Tax | 20.5M | 9.8M | 214.6M | 300.2M | 339.5M |
| Pre-Tax Margin | 1.9% | 0.8% | 12.6% | 14.5% | 12.5% |
| Income Tax Expense | 3.7M | 5.2M | 8.3M | (118.1M) | 92.4M |
| Net Income | 16.8M | 4.6M | 206.3M | 418.3M | 247.1M |
| Net Margin | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% |
| EPS (Basic) | 0.25 | 0.07 | 2.96 | 5.97 | 3.51 |
| EPS (Diluted) | 0.25 | 0.07 | 2.94 | 5.78 | 3.48 |
| Weighted Avg Shares | 67.7M | 69.38M | 69.75M | 70.08M | 70.35M |
| Weighted Avg Shares (Diluted) | 68.58M | 69.91M | 73.63M | 73.89M | 71.89M |
Insulet Corporation
NASDAQ:PODD
Intrinsic Alpha fair value
Locked
Current Price
$139.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.